[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-mineral-density\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-mineral-density":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,81,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100643860","multidimensional-determinants-of-functional-health-in-women-aged-45-60-100643860",false,"NCT07667699","Multidimensional Determinants of Functional Health In Women Aged 45-60","Multidimensional Determinants and Structural Foundations of Functional Health In Women Aged 45-60: The Role of Muscle and Bone Health","Inclusion Criteria are:\n\n* Women aged 45 to 60 years\n* Ability to read and complete study questionnaires\n* Provision of written informed consent\n* Ability to complete physical performance assessments\n\nExclusion Criteria are:\n\n* Acute systemic illness\n* Active malignancy\n* Severe neurological or orthopedic impairment limiting physical performance assessment\n* Cognitive impairment precluding informed consent or questionnaire completion",true,"FEMALE","45 Years","60 Years",{"count":21,"type":22},200,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this observational study is to learn about the multidimensional determinants of functional health in women aged 45 to 60 years. The study will focus on the role of muscle strength, bone mineral density, body composition, physical activity, sleep quality, depressive symptoms, and menopause-related symptoms in functional health.\n\nThe main questions it aims to answer are:\n\n1. Does muscle strength contribute to functional health in women aged 45 to 60 years?\n2. Does bone mineral density contribute to functional health in women aged 45 to 60 years?\n3. How are physical activity, sleep quality, depressive symptoms, body composition, and menopause-related quality of life associated with functional health?\n\nParticipants will:\n\n* Undergo handgrip strength measurement\n* Perform a 30-second chair stand test\n* Undergo bone mineral density and body composition assessment\n* Complete questionnaires about physical activity, sleep quality, depressive symptoms, menopausal symptoms, and quality of life\n* Provide demographic and clinical information",[27,28,29,30,31,32,33],"Healthy","Perimenopausal Depression","Menopausal Complaints","Bone Mineral Density","Sarcopenia","Sleep Quality","Quality of Life",[35,36,37,31,32,38],"Menopause","Perimenopause","Bone mineral density","Quality of life","NOT_YET_RECRUITING","2026-06-19",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":22},"2026-06-15",{"date":47,"type":22},"2026-12-31",{"name":49,"class":50},"Kartal City Hospital","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100572068","a-study-of-amorphous-calcium-carbonate-in-postmenopausal-women-100572068","NCT06728462","A Study of Amorphous Calcium Carbonate in Postmenopausal Women","A Study Benchmarking FREEDOM Substudy to Evaluate the Effects of Amorphous Calcium Carbonate in Postmenopausal Women","Inclusion Criteria:\n\n1. Postmenopausal women who are 60 to 90 years of age.\n2. With BMD T-score of lower than -2.5 at the lumbar spine or total hip and -4.0 or higher at both sites. Subject who also meet the following criteria:\n\n   A arm:-Subject who meet National Health Insurance (NHI) reimbursement criteria for use of denosumab.\n\n   B arm:-Subject who does not meet NHI reimbursement criteria for use of denosumab, or who is no willing to receive denosumab treatment during study period, even meet NHI reimbursement criteria.\n3. Subject who are naïve to osteoporosis treatment or have received prior bisphosphonate treatment for less than 3 years and not within 12 months prior to screening visit.\n4. A minimum of 2 evaluable lumbar vertebrae in the L1-L4 region and 1 evaluable hip (i.e., either the left or right side).\n5. Willingness to limit additional Vitamin D3 intake to 400IU or 800IU per day during the study period.\n6. Ability to complete the entire procedure and to comply with study instructions.\n7. Will provide completed and signed written informed consent.\n\nExclusion Criteria:\n\n1. Subjects who had conditions that influence bone metabolism (i.e., Paget's disease and osteomalacia).\n2. Subject on other osteoporosis therapies, parathyroid hormone or its derivatives, corticosteroids, systemic hormone-replacement therapy, selective estrogen-receptor modulators, tibolone, calcitonin or calcitriol 6 weeks prior to screening visit.\n3. Subjects had a serum 25-hydroxyvitamin D level of less than 12 ng\u002Fml.\n4. Subjects had a BMD T-score of less than -4.0 at the lumbar spine or total hip.\n5. Subjects with any severe or more than two moderate vertebral fractures on spinal x-ray at screening visit.\n6. Subject who plan to initiate a new bisphosphonate treatment during study period.\n7. Known hypersensitivity to any component of the study drug product.\n8. Participation in any other investigational study within 30 days prior to receiving study medication.\n9. Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety.","90 Years",{"count":60,"type":22},205,"INTERVENTIONAL",[63],"NA","Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.",[66,67,30,68,69],"Calcium","Osteoporosis","Bone Turnover Marker","Denosumab","RECRUITING","2025-03-04",{"date":73,"type":43},"2025-03-07",{"date":71,"type":43},{"date":76,"type":22},"2027-03-01",{"name":78,"class":79},"Universal Integrated Corp.","INDUSTRY",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":61,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100557513","phase-3-fluzoparib-in-combination-with-apatinib-mesylate-for-maintenance-therapy-in-stage-iii-iv-ovarian-cancer-100557513","NCT06539091","Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer","A Single-Arm, Open, Multicenter, Exploratory Clinical Study of Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer (FAT-1)","Inclusion Criteria:\n\n* ECOG PS: 0-1;\n\n  * Initially treated patients with histologically or cytologically confirmed high-grade plasma ovarian cancer (HGSOC), fallopian tube cancer, primary peritoneal cancer, or endometrioid carcinoma of the ovary with FIGO stage III-IV;\n\n    * No prior maintenance therapy with PARP inhibitors; ④Final use of a combination chemotherapy regimen of bevacizumab, paclitaxel and carboplatin; ⑤Good function of major organs; ⑥Subjects voluntarily enrolled in this study, signed an informed consent form, had good compliance, and cooperated with follow-up visits; ⑦The modeled CA-125 ELIMination rate constant K (KELIM) ≥ 1.\n\nExclusion Criteria:\n\n* Patients concurrently enrolled in other clinical trials;\n\n  * Previous maintenance therapy with PARP inhibitors combined with anti-angiogenic drugs;\n\n    * Previous history of allergic reaction, hypersensitivity reaction, intolerance to antibody-based drugs;\n\n      * Previous significant allergy to drugs or food or other substances;\n\n        * Subjects with untreated CNS metastases, previously treated with systemic, radical brain or meningeal metastases (radiotherapy or surgery), may be included if imaging confirms that stabilization has been maintained for at least 1 month and systemic hormone therapy (dose \\>10mg\u002Fday prednisone or other isotonic hormones) has been discontinued for \\>2 weeks without clinical evidence;\n\n          * Those who are unable to swallow tablets normally, or have abnormal gastrointestinal function that, in the judgment of the investigator, may interfere with drug absorption;\n\n            * Have experienced clinically significant bleeding symptoms or have a clear bleeding tendency within 3 months prior to randomization, such as peptic bleeding, bleeding gastric ulcer or suffering from vasculitis, etc. If the fecal occult blood is positive at the baseline period, it can be reviewed, and if it is still positive after review, combined with the clinical judgment, and if necessary, gastroscopy can be performed; ⑧The presence of currently uncontrolled malignant pleural fluid, ascites or pericardial effusion (defined as not effectively controlled by diuretics or puncture, as judged by the investigator);\n\n              * Presence of uncontrolled comorbidities including, but not limited to: active HBV or HCV infection, known HIV infection or history of AIDS, active syphilis, active tuberculosis, active infections, uncontrolled hypertension, symptomatic cardiac insufficiency, and active bleeding;\n\n                * Previous (within 5 years) or concurrent other untreated malignant tumors, except for cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and breast cancer without recurrence \\> 3 years after completion of radical surgery; ⑪Women during pregnancy or lactation; ⑫Having taken a drug that clearly affects the study drug within 30 days or 5 half-lives (whichever is longer) prior to enrollment; ⑬In the judgment of the investigator, the subject has other factors that may cause this study to be forcibly terminated midway, such as other serious illnesses (including psychiatric illnesses) that require comorbid treatment, serious laboratory test abnormalities, accompanied by family or social factors that would affect the subject's safety, or the collection of data and samples.","18 Years","75 Years",{"count":91,"type":22},51,[93],"PHASE3","This study is a single-arm, open, multicenter, exploratory clinical study to observe and evaluate the efficacy and safety of fluazoparib combined with apatinib mesylate in the treatment of patients with ovarian cancer.\n\nPatients with epithelial ovarian, fallopian tube, and primary peritoneal cancers will be selected as the study population with Progression-Free Survival (PFS) as the primary study endpoint, and Overall Survival (OS), Duration Of Response (DOR), Quality of Life Score QoL, Chemotherapy-Free Interval (CFI), Progression-Free Survival 2 (PFS-2), CA125 response criteria by GCGI, to access the safety、Bone Mineral Density (BMD) changes and the tolerability of fluazoparib in combination with apatinib mesylate.\n\nThe study is planned to enroll 51 subjects, all of whom will receive study treatment after being signed informed and screened.",[96,97,98,30,99],"Epithelial Ovarian Cancer","Efficacy","Safety","Tolerability","2024-08-03",{"date":102,"type":43},"2024-08-06",{"date":104,"type":22},"2024-10-01",{"date":106,"type":22},"2026-10-01",{"name":108,"class":109},"Anhui Provincial Hospital","OTHER_GOV",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":88,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":80},"100542178","the-bone-metabolism-characteristics-of-premature-ovarian-insufficiency-100542178","NCT06339489","The Bone Metabolism Characteristics of Premature Ovarian Insufficiency","Explore the Bone Metabolism Characteristics of Premature Ovarian Insufficiency","POI","Inclusion Criteria:\n\nPatients diagnosed by Western medicine with premature ovarian insufficiency. 18 ≤ patients' age ≤ 39 years;. Patients who voluntarily participate in this study, sign an informed consent form.\n\nExclusion Criteria:\n\nPatients with congenital gonadal dysplasia or a family history similar to \"early menopause\".\n\nPOI patients with acquired organic lesions or ovarian surgery. Patients who have taken Western or herbal medicine artificial cycle therapy or other endocrine therapy in the past three months.\n\nPatients with serious primary diseases and mental disorders such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system.\n\nPatients who are breastfeeding or pregnant.","39 Years",{"count":120,"type":22},60,"Explore the bone metabolism characteristics of premature ovarian insufficiency.",[123,124,30],"Premature Ovarian Insufficiency","Bone Diseases, Metabolic","2024-06-21",{"date":127,"type":43},"2024-06-25",{"date":129,"type":43},"2024-04-01",{"date":131,"type":22},"2025-02-01",{"name":133,"class":50},"Shi Yun"]